Brilife Coronavirus Vaccine Description
Brilife is a recombinant vesicular stomatitis virus (VSV), an animal virus that does not cause disease in humans, and where the spike protein was replaced with that of SARS-CoV-2 that “results in rapid and potent induction of neutralizing antibodies against SARS-CoV-2.
On June 19, 2020, a non-peer-reviewed study concluded 'the generated rVSV-ΔG-spike, a recombinant replication-competent VSV-based vaccine candidate expressing the SARS-CoV-2 spike protein. The rVSV-ΔG-spike resembles the SARS-CoV-2 in spike expression properties, antigenicity, and ability to induce neutralizing antibody production. Moreover, single-dose vaccination of hamsters with rVSV-ΔG-spike elicits a safe, effective, and sufficient neutralizing antibody response against the SARS-CoV-2 challenge.
The vaccination provided protection against SARS-CoV-2 inoculation, as manifested in the rapid return to normal physiological parameters lung protection and rapid viral clearance. These results pave the way for further examination of rVSV-ΔGspike in clinical trials as a vaccine against SARS-CoV-2.'
“Our final goal is 15 million doses for the residents of the State of Israel and for our close neighbors,” said Prof. Shmuel Shapira, director of the Israel Institute for Biological research, reported local media on October 26, 2020.
Sheba Medical Center and Hadassah Medical Center stated they were chosen for the initial trials of a COVID-19 vaccine. Both of these Israeli hospitals were selected because they have large facilities for clinical research.
The Israel Institute for Biological research (IIBR) was established in 1952 as a governmental research institute, founded by a group of scientists from the IDF Science Corps and from academic organizations. IIBR is located in the city of Ness Ziona, Israel.
Brilife Coronavirus Vaccine Indication
Brilife is indicated to prevent COVID-19 disease from infection with the virus SARS-CoV-2.
No pediatric vaccine efficacy has been disclosed.
Brilife Coronavirus Vaccine News
November 14, 2020 - Hadassah-University Medical Center has vaccinated 23 people against the novel coronavirus using the Israel Institute for Biological Research’s coronavirus vaccine candidate Brilife, the hospital said Friday. “All 23 participants in their 20s to 50s have had the vaccine in the last two weeks and are feeling well,” said Prof. Yossi Karko, director of the Center for Clinical Research at Hadassah. “They have not suffered from any unusual side effects or medical problems following the vaccine, other than temporary sensitivity at the site of injection – as expected.”
November 8, 2020 - Four women who were selected to participate in the human trial of "Brilife," the Israeli Institute for Biological Research's coronavirus vaccine, were vaccinated at Hadassah University Medical Center in Jerusalem's Ein Kerem. All four women were in their 20s - 30s and had been medically tested and found suitable to participate in the trial.
November 1, 2020 - The human trial of Brilife, its coronavirus vaccine candidate, launched by injecting two people – one at Hadassah-University Medical Center in Jerusalem's Ein Kerem and one at Sheba Medical Center at Tel Hashomer.
October 26, 2020 - Testing of the BriLife vaccine developed at Israel Institute for Biological Research begins at Hadassah and Sheba medical centers on healthy volunteers.
October 20, 2020 - Israel names its coronavirus vaccine candidate: Brilife.
June 21, 2020 - ISRAEL21c reported that a single dose of the IIBR’s recombinant VSV-∆G-spike vaccine “results in rapid and potent induction of neutralizing antibodies against SARS-CoV-2” in Syrian golden hamsters in a successful preclinical trial. It was also tested successfully in mice, rabbits, and pigs, paving the way to human trials.
Brilife Coronavirus Vaccine Clinical Trials
Clinical Trial NCT04608305: Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine
- In this Phase 1 study, a vaccine developed by IIBR for SARS-CoV-2 virus will be assessed for its safety and potential efficacy in volunteers.
- The study is comprised of two phases, a dose-escalation phase (phase I) during which subjects (18-55 years old) will be randomly allocated to receive a single administration of IIBR-100 100 at low, mid or high dose or saline or two administrations of IIBR-100 at a low dose, or saline, 28 days apart.
- Based on results obtained during phase I and cumulative phase I data review, the expansion phase (phase II) will begin, during which larger cohorts, as well as elderly age subjects, will be randomly allocated to receive a single administration of IIBR-100 at low, mid or high dose or saline, or two administrations of IIBR-100 at low dose (prime-boost) or saline, 28 days apart.
- The subjects will be followed for a period of up to 12 months post last vaccine administration to assess the safety and efficacy of the vaccine.
Phase 3 large scale trial is expected to begin in the spring of 2021 and will test the effectiveness of Brilife with up to 30,000 volunteers.